CureVac NV (WBO:CVAC) Total Stockholders Equity : €602.27 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Total Stockholders Equity?

CureVac NV's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €602.27 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. CureVac NV's Book Value per Share for the quarter that ended in Sep. 2023 was €2.69. The ratio of a company's debt over equity can be used to measure how leveraged this company is. CureVac NV's Debt-to-Equity for the quarter that ended in Sep. 2023 was 0.07.

CureVac NV Total Stockholders Equity Historical Data

The historical data trend for CureVac NV's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Total Stockholders Equity Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Total Stockholders Equity

32.08

-42.80

711.35

688.48

533.25

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Stockholders Equity	Get a 7-Day Free Trial														624.99	533.25	713.40	649.05	602.27

CureVac NV (WBO:CVAC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

CureVac NV's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(602.265	-	0)	/	223.924
	=	2.69

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

CureVac NV's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.534	+	36.58)	/	602.265
	=	0.07

CureVac NV Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of CureVac NV's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.